Home
About
Team
JOTROL™
JOTROL™ Pre-Clinical Studies
Pipeline
Friedreich's Ataxia (JOT101)
>
JOT101 Project Advisors
Alzheimer's Disease (JOT108)
Partners
News
Contact
Investors
Resveratrol science
Policies
Menu
Home
About
Team
JOTROL™
JOTROL™ Pre-Clinical Studies
Pipeline
Friedreich's Ataxia (JOT101)
>
JOT101 Project Advisors
Alzheimer's Disease (JOT108)
Partners
News
Contact
Investors
Resveratrol science
Policies
Results from the Phase I Pharmacokinetics Study will be cross-referenced, works as an FDA "master file", for all future
JOT
ROL
™
indications enabling direct to Phase II trials. Phase I results to be available by end of Q1,2021.
Home
About
Team
JOTROL™
JOTROL™ Pre-Clinical Studies
Pipeline
Friedreich's Ataxia (JOT101)
>
JOT101 Project Advisors
Alzheimer's Disease (JOT108)
Partners
News
Contact
Investors
Resveratrol science
Policies